MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Down 2.4% - What's Next?

Key Points

• MAIA Biotechnology's stock declined by 2.4% on Wednesday, trading as low as $1.60 before closing at $1.61 with a significant drop in trading volume, down 66% from its average.
• Director Stan Smith increased his ownership by purchasing 33,333 shares at an average price of $1.50, bringing his total holdings to over 1.3 million shares.
• An institutional investor, Jane Street Group LLC, acquired a new position in MAIA Biotechnology, purchasing 39,057 shares valued at approximately $77,000.

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) shares fell 2.4% on Wednesday . The company traded as low as $1.60 and last traded at $1.61. 181,152 shares changed hands during mid-day trading, a decline of 66% from the average session volume of 532,497 shares. The stock had previously closed at $1.65.

MAIA Biotechnology Price Performance

The company has a fifty day moving average of $1.76 and a 200-day moving average of $1.83. The firm has a market capitalization of $46.07 million, a PE ratio of -1.92 and a beta of 0.02.

Insider Activity

In other news, Director Stan Smith bought 33,333 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were purchased at an average price of $1.50 per share, for a total transaction of $49,999.50. Following the acquisition, the director directly owned 1,305,059 shares of the company's stock, valued at $1,957,588.50. The trade was a 2.62% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 32.32% of the company's stock.

Institutional Trading of MAIA Biotechnology

A hedge fund recently bought a new stake in MAIA Biotechnology stock. Jane Street Group LLC purchased a new position in shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 39,057 shares of the company's stock, valued at approximately $77,000. Jane Street Group LLC owned about 0.15% of MAIA Biotechnology at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.65% of the company's stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.